- Home
- URGN vs AHG Comparison
URGN vs AHG Comparison
Compare URGN & AHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- AHG
- Stock Information
- Founded
- URGN 2004
- AHG 2013
- Country
- URGN United States
- AHG China
- Employees
- URGN N/A
- AHG N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- AHG Business Services
- Sector
- URGN Health Care
- AHG Consumer Discretionary
- Exchange
- URGN Nasdaq
- AHG Nasdaq
- Market Cap
- URGN 831.6M
- AHG 765.9M
- IPO Year
- URGN 2017
- AHG N/A
- Fundamental
- Price
- URGN $19.22
- AHG $1.66
- Analyst Decision
- URGN Strong Buy
- AHG
- Analyst Count
- URGN 8
- AHG 0
- Target Price
- URGN $29.00
- AHG N/A
- AVG Volume (30 Days)
- URGN 1.3M
- AHG 91.7K
- Earning Date
- URGN 08-07-2025
- AHG 08-12-2025
- Dividend Yield
- URGN N/A
- AHG N/A
- EPS Growth
- URGN N/A
- AHG N/A
- EPS
- URGN N/A
- AHG N/A
- Revenue
- URGN $91,871,000.00
- AHG $8,454,946.00
- Revenue This Year
- URGN $39.80
- AHG N/A
- Revenue Next Year
- URGN $108.94
- AHG N/A
- P/E Ratio
- URGN N/A
- AHG N/A
- Revenue Growth
- URGN 8.98
- AHG 281.19
- 52 Week Low
- URGN $3.42
- AHG $0.74
- 52 Week High
- URGN $19.69
- AHG $2.35
- Technical
- Relative Strength Index (RSI)
- URGN 76.29
- AHG 50.13
- Support Level
- URGN $18.37
- AHG $1.55
- Resistance Level
- URGN $19.36
- AHG $2.10
- Average True Range (ATR)
- URGN 1.03
- AHG 0.25
- MACD
- URGN 0.25
- AHG -0.01
- Stochastic Oscillator
- URGN 91.26
- AHG 20.72
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.